Moffett

Kathryn S. Moffett, MD

Assistant Dean, Faculty Personnel & Faculty Services, Professor/Division Chief of Pediatric Infectious Diseases

Contact

Phone
304-598-4835
Fax
304-293-1216
Address
PO Box 9214
Department of Pediatrics
Division of Infectious Disease, Mountain State Cystic Fibrosis Center
Morgantown, WV 26506-9214
View Clinical Profile
Additions & Corrections?

Positions

Assistant Dean, Faculty Personnel & Faculty Services, Professor/Division Chief of Pediatric Infectious Diseases

Organization:
School of Medicine
Department:
Pediatrics
Classification:
Clinical Faculty

Education

  • MD, Pennsylvania State University, Hershey, PA

Publications

Manuscripts: 

  1. Akers SM, Yossuck P, Kiefer AS, Mitchell ML, Moffett KS. Rash in an extremely low birth weight infant. Annals Infect Dis Epidem. Accepted for publication, November 2018.
  2. Gonzalez D, James LP Al-Uzri A, Bosheva M, Adler-Shohet FC, Mendley SR, Bradley JS, Espinosa C, Tsonkova E, Moffett K, Marquez L, Simonsen KA, Stoilov S, Boakye-Agyeman F, Jasion T, Hornik CP, Hernandez R, Benjamin DK Jr, Cohen-Wolkowiez M. Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00692-18.
  3. Schechter MS ,VanDevanter DR, Pasta DJ, Short SA, Morgan WJ, Konstan MW; for the Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett K. Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Ann Am Thorac Soc Vol 15, No 2, pp 225–233, Feb 2018.
  4. Biondo L, Duncan C, Toucheque M, Farley A, Moffett K. A Quality Improvement Initiative to Improve Patient Adherence to Vitamin Supplementation in Cystic Fibrosis. J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):292-295.
  5. Purewal R, Costello L, Garlapai S, Mitra S, Mitchell M, Moffett K. Congenital Herpes Simplex Virus in the Newborn –A Diagnostic Dilemma. J Pediatric Infect Dis Soc. 2016 Sep;5(3):e21-3. doi: 10.1093/jpids/piw013. Epub 2016 Mar 28.
  6. Gioia L, Leys M, Bonsall D, Moffett K.  Bilateral maculopathy in a patient with ataxia telangiectasia. Journal of  AAPOS. 2016; Feb:20 (1):85-88.
  7. Rosenfeld M, VanDevanter DR, Ren CL, Elkin EP, Pasta DJ, Konstan MW, Morgan WJ; Investigators of Coordinators of the Epidemiologic Study of Cystic Fibrosis including Moffett K. Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. Pediatr Pulmonol. 2015 Sep;50(9):856-62.
  8. Bradley JS, Armstrong J, Arrieta A, Bishai R, Das S, Delair S, Edeki T, Holmes WC, Li J, Moffett KS, Mukundan D, Perez N, Romero JR, Speicher D, Sullivan JE, Zhou D. Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6252-9.
  9. Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis, including Moffett K. Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016 Feb;169:116-21. Erratum in: J Pediatr. 2018 Jun;197:322.
  10. Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, Schwarzenberg SJ and the STRIVE study investigators including Moffett K. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Dig Dis Sci. 2015 Aug 7.
  11. Lynch J, Patra KP, Vijay C, Mitchell M, Moffett-Bradford K.A Case of Fever of Unknown Origin. Hosp Pediatr. 2015 Aug;5(8):452-5.
  12. Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus , Castiglione B, Vera-Llonch M and the STRIVE investigators including Moffett K.. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial.  Health Qual Life Outcomes. 2015 Jul 2;13:93.
  13. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group including Moffett K. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Jul 16;373(3):220-31.
  14. Helshe SL, Mayer-Hamblett N, Burns JL, et al and the GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network, including Moffett KS. Pseudomonas aeriginosa in Cystic Fibrosis Patients With G551D-CFTR Treated with Ivacaftor. CID. 2015. 60(1 March): 703-712.
  15. Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM; GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network including Moffett KS.  Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015 Mar 1;60(5):703-12.
  16. Stanley J, Guilfoose J, Simmons M, LaSala P, Moffett KS.  Recurrent Fever in a Healthy 30-Year-Old Pregnant Female. J Bacterio Parasit 2015 V 5 ( 5).
  17. Collaco JM, Blackman SM, Raraigh KS, Morrow CB, Cutting GR, Paranjape SM, and the Twin Sibling Study Group, including Moffett K. Self-reported exercise and longitudinal outcomes in cystic fibrosis: a retrospective cohort study. BMC Pulm Med. 2014 Oct 6;14:159.
  18. Tullis DE, Burns JL, Retsch-Bogart GZ, Bresnik M, Henig NR, Lewis SA, Lipuma JJ, and the AZLI Burkholderia Study Group including Moffett K. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros. 2014 May;13(3):296-305.
  19. Rowe S, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network including Moffett KS. Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis, Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84.
  20. Quittner AL, Goldbeck L, Abbott J et al and the Depression Epidemiologic Study Group including Moffett KS.  Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014 Sep 21. pii: thoraxjnl-2014-205983. doi: 10.1136/thoraxjnl-2014-205983.
  21. Carey ME, Moffett KS, Baer LS, Haut MW; Neurocognitive Function and White Matter Integrity in Adolescents with Cystic Fibrosis. Journal of Cystic Fibrosis; 2013.
  22. Crook J, Evans M, Floyd H, Scaffel  R, Vincent M, Mancinelli, C, Landvoigt M, Moffett K, Swisher A. Correlation of cystic fibrosis related diabetes with sensation gate characteristics and balance. J Stud Phys Ther Res , 2013; 63 (4) 36-41.
  23. Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators including Moffett KS.  Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2.
  24. Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis including Moffett KS.  Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr. 2013 Oct;163(4):1152-7.e2.
  25. Saiman L, Mayer-Hamblett N, Anstead M, Lands LC, Kloster M, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Macrolide Study Team including Moffett KS.  Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol. 2012 Jul;47(7):641-8.
  26. Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group including Moffett KS.  Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros. 2012 Dec;11(6):539-49.
  27. Borowitz D, Stevens C, Brettman LR, Campion M, Wilschanski M, Thompson H; Liprotamase 767 Study Group including Moffett KS.  Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):248-57.
  28. Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis including Moffett KS. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol. 2013 Jul 2.
  29. Moffett KS, Pediatric Infection Disease: Unusual Head & Neck Infections. Oral Maxillofacial Surg Clin N Am 2012; 24:469-486.
  30. Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group including Moffett KS. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros. 2012 Dec;11(6):539-49. doi: 0.1016/j.jcf.2012.05.003. Epub 2012 Jun 8.
  31. VanDevanter DR, Yegin A, Morgan WJ, Millar SJ, Pasta DJ and MK Konstan. J and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS. Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. Cyst Fibr 2011; 10:453-459.
  32. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group, including Moffett K. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72.
  33. Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS. Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. J Pediatr. 2011 Nov;159(5):819-824.e1.
  34. Slain D, Sarwari A,Petros K, McKnight R, Sager R, Mullett C, Wilson A, Thomas J, Moffett K, Palmer HC, Dedhia H. Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit setting. Critical Care Research and Practice. vol. 2011, Article ID 416426.
  35. Moffett KS. Reflections of Myles. Pediatr Ann. 2011 May;40(5):282-3.
  36. Moffett KS, Tantocco, AM. Report of Increased Number of Children with Parapneumonic Empyema as a Complication of Bacterial Pneumonia in West Virginia in 2005. WV Med J 2011; 107(2):16-19.
  37. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, Morgan WJ; Scientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis including Moffett KS. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol. 2011 Jun;46(6):545-53. doi: 10.1002/ppul.21388. Epub 2011 Mar 24.
  38. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group including Moffett KS.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
  39. Borowitz D, Stevens C, Brettman LR, Campion M, Chatfield B, Cipolli M; Liprotamase 726 Study Group including Moffett KS.  International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros. 2011 Dec;10(6):443-52.
  40. Moffett KS, Shultz R, Ardito A. What’s Your Diagnosis? Infectious Diseases in Children. 2010 (23)12:14-15.
  41. Moffett KS, Grayson SA.  Should pediatricians be vaccinating the parents of patients (eg. with Tdap and flu vaccines)?  Consultant for Pediatricians.  2010;9(10):S13.
  42. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL and the Sputum Study Group, including Moffett KS. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatric Pulmonol. 2010 Apr;45(4):363-70.
  43. Oermann CM, retsch-Bogart GZ, Quittner AL,Gibson RL, McCoy KS, Montgomery AB, and the Azli Study Group, including Moffett KS. An 18-moth study of the safety and efficiay of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45:1121-1134.
  44. Saiman L, Anstead M, Mayer-Hamblett M, et al. and the AZ004 Azithromycin Study Group including Moffett K. Effect of Azithromycin on Pulmonary Function in Patients with Cystic Fibrosis Uninfected with Pseudomonas aeruginosa, A Randomized Controlled Trial. JAMA. 2010; 303(17):1707-1715.
  45. Konstan MW, Liou TG, Strausbaugh SD, Ahrens R, Kanga JF, Graff GR, Moffett K, Millard SL, Nasr SZ, Siméon E, Spénard J, Grondin J. Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Gastroenterol Res Pract. 2010;2010:898193.
  46. Swisher, A, Moffett K. The Effect of Coaching on Physical Activity and Quality of Life in Children and Adolescents with Cystic Fibrosis:  A Quality Improvement Pilot Study" Internet Journal of Allied Health Sciences and Practice (IJAHSP ) , 2010; Vol  8 ( 2): 1-7.
  47. Konstan MW, VanDevanter DR, Rasouliyan L, Pasta DJ, Yegin A, Morgan WJ, Wagener JS; Scientific Advisory Group; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis including Moffett KS. Trends in the use of routine therapies in cystic fibrosis: 1995-2005.  Pediatr Pulmonol. 2010 Dec;45(12):1167-72.
  48. Yossuck P, Miller-Canfield P, Moffett K, Graeber J. Leuconostoc spp. sepsis in an extremely low birth weight infant: a case report and literature review. WV Med J,2009; 105 (5): 24-27.
  49. Moffett KS.  Photo essay: Digital Clubbing, Consultant for Pediatricians.  2009; Vol 8 (3): 87-9.
  50. Moffett KS, What WV parents need to know about H1N1 (Swine Flu) threat. Parenting Perspectives-WV Bureau for Behavioral Health & Health Facilities. 2009; 18(1):21-22.
  51. Bartlett JR, Friedman KJ, Ling SC, et al and the Genetic Modifiers Group including Moffett KS. Genetic Modifiers of Liver Disease in Cystic Fibrosis JAMA. 2009 Sep 9;302(10):1076-1083.
  52. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis  including Moffett KS.   JAMA. 2009 Sep 9;302(10):1076-83.
  53. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis; North American Scientific Advisory Group for ESCF including Moffett KS.  Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr. 2009 Nov;155(5):634-9.
  54. Bernard RS, Cohen LL, Moffett K. A token economy for exercise adherence in pediatric cystic fibrosis: a single-subject analysis. J Pediatr Psychol. 2009 May;34(4):354-65. doi: 10.1093/jpepsy/jsn101. Epub 2008 Sep 26.
  55. McClellan CB, Cohen LL, Moffett K. Time out based discipline strategy for children's non-compliance with cystic fibrosis treatment. Disabil Rehabil. 2009;31(4):327-36. doi: 10.1080/09638280802051713.
  56. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L and the CF Foundation registry investigators including Moffett KS. Respiratory Microbiology of Patients with Cystic Fibrosis in the United States, 1995-2005.  Chest.  2009 June 8.
  57. Watts KD, Seshadri R, Sullivan C, McColley SA and the CF Foundation registry investigators including Moffett KS.Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF Population.   Pediatr Pulmonol.  2009 Jun:  44(6): 594-601
  58. Blackman SM, Hsu S, Ritter SE, Naughton KM, Wright FA, Drumm ML, Knowles MR, Cutting GR and the CF Gene Modifier Study Group including Moffett KS.  A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia. 2009 Jul 8.
  59. Blackman SM, Hsu S,  Vanscoy LL, Collaco JM, Ritter SE Naughton K, Cutting GR and the CF Twin & Sibling Study Group of Investigators/ Coordinators, including Moffett KS.  Genetic Modifiers Play a Substantial Role in Diabetes Complicating Cystic Fibrosis J Clin Endocrinol Metab. April 2009, 94(4):1302–1309.
  60. Moffett KS. Parent Coach Column, “Turtles and Hermit Crabs As Pets”, Consultant for Pediatricians, 2009; Vol 8 (3): 95.
  61. Taylor-Cousar JL, Zariwala MA, Burch LH, Pace RG, Drumm ML, Calloway H, Fan H, Weston BW, Wright FA, Knowles MR; and the CF Gene Modifier Study Group including Moffett KS. Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PLoS One. 2009;4(1):e4270. Epub 2009 Jan.
  62. Weisse  ME, Mullins JK, Moffett  KS. Photo Quiz. Clin Infec Dis 2008:46.
  63. Moffett KS, Streptococcal Infection secondary to varicella; Consultant for Pediatricians, 2008;7(9):924.
  64. Konstan MW and the CF Foundation registry investigators including Moffett KS Ibuprofen therapy for cystic fibrosis lung disease: revisited.  Curr Opin Pulm Med.   2008 Nov: 14(6): 567-73. Review.  
  65. Dasenbrook E, Merlo C, Diener-West M, et al and the CF Foundation registry investigators including Moffett KS. Persistent methicillin-resistant  Staphylococcus Aureus and Rate of FEV1 Decline in Cystic Fibrosis.  Am J Respir Crit Care Med. 2008 July 31.
  66. Lai HC, Shoff S, and the CF Foundation registry investigators including Moffett KS. Classification of malnutrition in cystic fibrosis: implications for evaluating and benchmarking clinical practice performance.  Am J Clin Nutr.  2008 July: 88(1): 161-6.
  67. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H and the CF Foundation registry investigators including Moffett KS.  Clinical Practice Guidelines on Growth and Nutrition Subcommittee: Ad Hoc Working Group. Evidence-based practice recommendation for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc.  2008 May: 108(5): 832-9 Review.
  68. Padman R, Werk LN, Ramirez-Garnica, et al and the CF Foundation registry investigators including Moffett KS. Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis.  J Cyst Fibros.  2008 Mar 12.
  69. Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (ESCF) including Moffett KS.  Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol. 2008 Sep;43(9):874-81.
  70. Bremer LA, Blackman SM, Vanscoy LL, McDougal KE, Bowers A, Naughton KM, Cutler DJ, Cutting GR and the CF Gene Modifier Study Group including Moffett KS.Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improving lung function in cystic fibrosis. Hum Mol Genet. 2008;17:2228-37.
  71. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB and the Clinical Investigators including Moffett KS. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8. Epub 2008 Jul 24.
  72. Hillian AD, Londono D, Dunn JM, Goddard KA, Pace RG, Knowles MR, Drumm ML; and the  CF Gene Modifier Study Group including Moffett KS.. Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun. 2008 Sep;9(6):501-8. Epub 2008 Jun 19.
  73. Bremer LA, Blackman SM, Vanscoy LL, McDougal KE, Bowers A, Naughton KM, Cutler DJ, Cutting GR. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis and the CF Twin & Sibling Study Group of Investigators/ Coordinators, including Moffett KS.  Hum Mol Genet. 2008 Jul 15;17(14):2228-37. Epub 2008 Apr 1
  74. Collaco JM, Vanscoy L, Bremer L, McDougal K, Blackman SM, Bowers A, Naughton K, Jennings J, Ellen J, Cutting GR and the CF Twin & Sibling Study Group of Investigators/ Coordinators, including Moffett KS.  Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA. 2008 Jan 30;299(4):417-24.
  75. Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, Hamosh A, Cutler D, Cutting GR and the CF Twin & Sibling Study Group of Investigators/ Coordinators, including Moffett KS.  Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med. 2007 May 15;175(10):1036-43. Epub 2007 Mar 1.
  76.  Konstan M, Schluter M, Davis PB and the CF Foundation registry investigators including Moffett KS.  Clinical Use of ibuprofen is Associated with Slower FEV1 Decline in Children with Cystic  Fibrosis.  Am J Respir Crit Care Med. 2007 Dec 1; 176 (11): 1084-9
  77. Liou TG, Adler FR, Cox DR, and Cahill BC and the CF Foundation registry investigators including Moffett KS. Lung transplantation and survival in children with cystic fibrosis.  N Engl j Med. 2007 Nov 22;357 (21):2143-52.
  78. Merlo CA,  Boyle MP, Diener-West, et al and the CF Foundation registry investigators including Moffett KS. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.  Chest. 2007  Aug;132(2): 562-8 Epub 2007 Jul 23 
  79.  Razvi S, Saiman L and the CF Foundation registry investigators including Moffett KS. ,Nontuberculous mycobacteria in cystic fibrosis. Pediatr Infect Dis J. 2007 Mar;26(3): 263-4.
  80. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.  Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr. 2008 Dec;153(6):733-5.
  81. Konstan MW, Morgan WJ, Butler SM, et al and the Investigators & Coordinators of the epidemiologic Study of Cystic Fibrosis , including Moffett KS. Risk factors for rate of decline in Forced Expiratory Volume in one second in children & adolescents with cystic fibrosis. J Pediatr 2007;151:134-9.
  82. McClellan CB, Cohen LL, Moffett KS. Time Out Based Discipline Strategy to Manage Children’s Noncompliance with Cystic Fibrosis Treatment. J Ped Psychol 2007.
  83. Vanscoy LL, Blackman SM, Collaco JM, et al and the CF Twin & Sibling Study Group, including Moffett KS. Heritability of lung disease severity in Cystic Fibrosis. Am J Respir Crit Care Med. 2007 Mar 1, e pub.
  84. Swisher AK, Baer L, Bonner D, Moffett KS.  Effect of habitual activity, lung function, and nutritional measurements on 3-minute step test performance in children with cystic fibrosis. Cardiopulm Phys Ther J 2007; 18(1) 15-20.
  85. Moffett KS. “Clinical Tip: How to Keep the Otoscope on the Clinical Ward”. Contemporary Pediatrics 2006.
  86. Moffett KS.  Night Terrors. Consultant For Pediatricians 2006; 5(10): 63-1.
  87. Blackman SM, Deering-Brose R, McWilliams R, Naughton K, Coleman B, Lai T, Algire M, Beck S, Hoover-Fong J, Hamosh A, Fallin MD, West K, Arking DE, Chakravarti A, Cutler DJ, Cutting GR and the CF Twin & Sibling Study Group of Investigators/ Coordinators, including Moffett KS.  Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology. 2006 Oct;131(4):1030-9. Epub 2006 Jul 24.
  88. Borowitz D, Goss CH, Limauro S, et al and the CF Study Group including Moffett KS. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr. 2006 Nov; 149(5):658-662.
  89. Blackman SM, Deering-Brose R, McWilliams, et al and the CF Twin and Sibling Study Group, including Moffett KS.  Relative contribution of genetic and non-genetic modifiers to intestinal obstruction in cystic fibrosis. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology. 2006 Oct; 131(4):1030-9. Epub 2006 Jul 24.
  90. McKone EF,Goss CH, Aitken ML and the CF Foundation registry investigators including Moffett KS.  CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006 Nov;130(5): 1441-7.
  91. Grosse SD,Rosenfeld M, Devine OJ, Lai HJ, Farrell PM and the CF Foundation registry investigators including Moffett KS.  Potential Impact of Newborn Screening for Cystic Fibrosis on Child Survival: A Systematic Review and Analysis. J Pediatr 2006 Sep: 149: 362-6.
  92. Goss CH, Rubenfeld GD,Ramsey BW,Aitken ML and the CF Foundation registry investigators including Moffett KS. Clinical trial participants compared with nonparticipants in cystic fibrosis. Am J Respir Crit Care Med.  2006 Jan 1:173(1):98-104. Epub 2005 Sep 28. 
  93. McMullen AH, Pasta DJ, Frederick PD and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.  Impact of pregnancy on women with cystic fibrosis. Chest. 2006 Mar; 129(3):706-11.
  94. Moffett KS, Welch J. Picture of the Month: a Trichobezoar in a 7 year old child.  Arch Pediatr Adolesc Med 2006; 160:499-500.
  95. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B and the CF Foundation registry investigators including Moffett KS. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2005 Oct 1;172(7):885-91. Epub 2005 Jun 23.
  96. Accurso FJ, Sontag MK, Wagener JS and the CF Foundation registry investigators including Moffett KS. Complication Associated with Symptomatic Diagnosis in Infants with Cystic Fibrosis. (J Pediatr 2005 Sep;147(3 Suppl):S37-41).
  97. Lai HJ, Cheng Y, Farrell PM and the CF Foundation registry investigators including Moffett KS. The Survival Advantage of Patients with Cystic Fibrosis Diagnosed through Neonatal Screening: Evidence from the United States Cystic Fibrosis Foundation Registry Dat. (j Pediatr 2005 Sep; 147(3 Suppl):S57-63).
  98. Flume PA, Yankaskas JR,et.al. and the CF Foundation registry investigators including Moffett KS. Massive Hemoptysis in Cystic Fibrosis.  (Chest. 2005 Aug; 128 (2):729-38).
  99. Flume PA,Strange C, et. Al. and the CF Foundation registry investigators including Moffett KS. Pneumothorax in Cystic Fibrosis.  (Chest. 2005  Aug; 128 (2): 720-8).
  100. Kulich M, Rosenfeld M,Campbell J, et.al. and the CF Foundation registry investigators including Moffett KS. Disease-Specific Reference Equations for lung function in Patients with Cystic Fibrosis. (Am J Respir Crit Care Med 2005 Jun; 172: 885-891).
  101. Drumm ML, Konstan MW, Schluchter MD, et al and the Gene Modifier Study Group, including Moffett KS. Genetic Modifiers of Lung Disease in Cystic Fibrosis. NEJM 2005; 353(14): 1443-1453.
  102. Baker SS, Borowitz D, Duffy L, Fitzpatrick L, Gyamfi J, Baker RD and the CF study group, including Moffett KS. Pancreatic enzyme therapy and outcomes in patients with Cystic Fibrosis.  J Pediatr 2005; 146:189-93.
  103. Swisher AK, Moffett K, Baer L. The impact of cystic fibrosis on recovery from orthopedic trauma: a case study. J Cyst Fibros. 2005 Dec;4(4):263-5. Epub 2005 Sep 16.
  104. Swisher AK, Yeater R, Moffett KS, Baer, L The Influence of Lean Body Mass and Leg Muscle Strength on 6-Minute Walk Test Performance in Children with Cystic Fibrosis.  Cardiopulmonary Physical Therapy J 2005; 16(3):5-9.
  105. Moffett K, Cool way to make hot food edible: Clinical Tip, Contemporary Pediatrics; 2005; 22(1) 79.
  106. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR; and the CF Gene Modifier Study Group including Moffett KS.. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005 Oct 6;353(14):1443-53.
  107. Marshall BC, Butler SM, Stoddard, M, et al and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.  Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005 May; 146(5):681-7.
  108. Moffett KS.  Streptococcal Infection Secondary to Varicella. Consultant for Pediatrics; 2004; 3(2): 98.
  109. Grosse SD, Boyle CA, Botkin JR, et.at. and the CF Foundation registry investigators including Moffett KS.Newborn Screening for Cystic Fibrosis: Evaluation of Benefits and Risks and Recommendations for State Newborn Screening Programs. (MMWR Recomm Rep 2004 Oct 15;53(RR-13):1-36).
  110. Goss CH,  Sucharew H, McKone EF,et.al and the CF Foundation registry investigators including Moffett KS. Nutritional  Supplementation in the US Adult Cystic Fibrosis(CF) Population with Severe Pulmonary Impairment. (Pediatric Pulmonology. 2004 Oct).
  111. Patrick M, Campbell P, Durie P, Lowenfels AB and the CF Foundation registry investigators including Moffett KS. Pancreatitis in Hispanic Patients with Cystic Fibrosis Carrying the R334W Mutation. ( Clin Gastroenterol Hepatol 2004 Jun; 2:504-509.)
  112. Borowitz D, Baker SS, Duffy L, Baker RD, Fitzpatrick L, Gyamfi J, Jarembek K. and the CF study group, including Moffett KS. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr. 2004 Sep; 145(3):322-6.
  113. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE; and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.  Pulmonary exacerbations in cystic fibrosis Pediatr Pulmonol. 2004 May; 37(5):400-6.
  114. Goss CH, Newsom SA, Schildcrout JS, Sheppard L, Kaufman JD and the CF Foundation registry investigators including Moffett KS. Effect of Ambient Air Pollution on Pulmonary Exacerbations and Lung Function in Cystic Fibrosis.  (Am J Respir Crit Care Med.  2004 Apr 1;169(7):816-21).
  115. Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM and the CF Foundation registry investigators including Moffett KS.Association between Initial Disease Presentation, Lunch Disease Outcomes, and Survival in Patients with Cystic Fibrosis. (Am J Epidemiol  2004:159:537-546).
  116. Goss Ch, RubenfeldGD, Otto K, Aitken ML and the CF Foundation registry investigators including Moffett KS.The Effect of Pregnancy on Survival in Women with Cystic Fibrosis.  Chest. 2003 Oct; 124 (4): 1460-68).
  117. Mogayzel PJ and the CF Foundation registry investigators including Moffett KS. How to Manage Advanced Lung Disease in Cystic Fibrosis.  (The Journal of Respiratory Diseases for Pediatricians 2003 July/August; 163-169).
  118. Kulich M, Rosenfeld M, Goss CH, Wilmott R and the CF Foundation registry investigators including Moffett KS.
  119. Improved Survival Among Young Patients with CF.  (J Pediatr.  2003 Jun;142 (6) 631-6).
  120. McKone EF,Emerson SS,Edwards KL, Aitken ML and the CF Foundation registry investigators including Moffett KS. Effect of Genotype on Phenotype and Mortality in Cystic Fibrosis: A Retrospective Cohort Study. (Lancet. 2003 May 17; 361:1671-76).
  121. O’Connor GT, Quinton HB, Kneeland T, Kahn R,et.al. and the CF Foundation registry investigators including Moffett KS. Median Household Income and Mortality Rate in CF. Pediatrics 2003 Apr;111(4 Pt 1):e333-9.
  122. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N,  Accurso  F, et. Al. and the CF Foundation registry investigators including Moffett KS. Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. Am J  Resp Critical Care Medicine.  2003 March 15;167(6):841-9).
  123. Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R, Wagener JS, Johnson CA, Morgan WJ, and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS . Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis J Pediatr. 2003 Jun;142(6):624-30.
  124. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.  Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest. 2003 Jan;123(1):20-7.
  125. O'Connor GT, Quinton HB, Kneeland T, Kahn R, Lever T, Maddock J, Robichaud P, Detzer M, Swartz DR and the U.S. Cystic Fibrosis Foundation (CFF) National Patient Registry, including Moffett KS.  Median household income and mortality rate in cystic fibrosis. Pediatrics. 2003 Apr;111(4 Pt 1):e333-9.
  126. Swisher AK, Yeater R, Moffett KS, Baer, L, Stanton, B.  A comparison of methods to Determine Body Fat in Individuals with Cystic Fibrosis: A Pilot Study.  J Exercise Physio 2003; 6 (2): 105-114.
  127. Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB and the CF Foundation registry investigators including Moffett KS. Cancer Risk in Nontransplanted and Transplanted Cystic Fibrosis Patients: A 10-Year Study.  (Journal of the National Cancer Institute. 2003 mar 5;95(5):381-7).
  128. Accurso FJ, Sontag MK and the CF Foundation registry investigators including Moffett KS. Seeking Modifier Genes in Cystic Fibrosis.  (American Journal of Respiratory and Critical Care Medicine.  2003 February 1:167 (3):289-90).
  129. Moran A, Milla C and the CF Foundation registry investigators including Moffett KS. Abnormal Glucose Tolerance in Cystic Fibrosis: Why Should Patients be Screened?  (Journal of Pediatrics.  2003 February 1;142(2):97-9).
  130. Goss CH and the CF Foundation registry investigators including Moffett KS. Airway Clearance in Cystic Fibrosis (Respiratory Care.  2003 Jan; 48(1):20-1).
  131. Stallings VA and the CF Foundation registry investigators including Moffett KS. Gender, Death and Cystic Fibrosis: Is Energy Expenditure a Component? (Journal of Pediatrics; 2003 January; 142 (1): 4-6).
  132. Flume PA and the CF Foundation registry investigators including Moffett KS. Pneumothorax in Cystic Fibrosis.  Chest.  203 Jan; 123 (1):217-21.
  133. Mayer-Hamblett N. Rosenfeld M, Emerson J, Goss CH, Aitken ML and the CF Foundation registry investigators including Moffett KS. Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year Mortality. (American Journal of Respiratory and Critical Care Medicine. 2002 December 15; 166(12 Pt1):1550-5).
  134. Wang SS, O’Leary LA, FitzSimmons, SC, Shoury MJ and the CF Foundation registry investigators including Moffett KS. The Impact of Early Cystic Fibrosis Diagnosis on Pulmonary Function in Children.  (Journal of Pediatrics 2002. Dec; 141 (6): 804-10).
  135. Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR and the CF Foundation registry investigators including Moffett KS. Variant Cystic Fibrosis Phenotypes in the Absence of CFTR Mutations. (New England Journal of Medicine.  2002 August 8;347 (6):401-7).
  136. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL and the U.S. Cystic Fibrosis Foundation (CFF) National Patient Registry, including Moffett KS.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002 Aug;34(2):91-100.
  137. C.H. Goss, K. Otto, M.L. Aitken and the CF Foundation registry investigators including Moffett KS. Detecting Stenotophomonas maltophila does not Reduce Survival of Patients with Cystic Fibrosis.  (American Journal of Respiratory and Critical Care Medicine.  2002 August 1; 166(3):356-61).
  138. J Emerson, M Rosenfeld, S McNamara, et.al. and the CF Foundation registry investigators including Moffett KS.Pseudomonas aeruginosa and other Predictors of Mortality and Morbidity in Young Children with Cystic Fibrosis.  (Pediatric Pulmonology 2002. August;34(2):91-100).
  139. Lai HC,  Kosorok MR,  Laxova A,  Makholm LM, Farrell PM and the CF Foundation registry investigators including Moffett KS. Delayed diagnosis of US females with cystic fibrosis. Am J Epidemiol. 2002 Jul 15:156(2):165-73.
  140. Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC and the CF Foundation registry investigators including Moffett KS. Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. Genet Med 2002 Mar-Apr;4(2):90-4.
  141. O’Connor GT, Quinton HB, Kahn R, Robichaud P, Madock J, Lever T, Detzer M, Brooks JG; Northern New England Cystic Fibrosis Consortium and the CF Foundation registry investigators including Moffett KS.Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmonol 2002 Feb;33(2):99-105.
  142. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH and the CF Foundation registry investigators including Moffett KS. Lung Transplantation for Cystic Fibrosis Patients with Burholderia cepacia Complex. Survival Linked to Genomovar Type. (American Journal of Respiratory and Critical Care Medicine. 2001 Dec 1;164(11):2102-6).
  143. Saiman L, TabibiS, Starner TD, et. al. and the CF Foundation registry investigators including Moffett KS. Cathelicidin Peptides Inhibit Multiply Antibiotic-resistant Pathogens from Patients with Cystic Fibrosis. (Antimicrobial Agents and Chemotherapy 2001. Oct;45(10):2838-44).
  144. Liou TG, Adler FR, Cahill BC, et.al. and the CF Foundation registry investigators including Moffett KS.
  145. Survival Effect of Lung Transplantation for Patients with Cystic Fibrosis. (JAMA; 2001;286:2686-2689).
  146. Swisher AK, Yeater R, Moffett K, Baer L, Stanton B. Gender differences in predictors of 6-minute walk performance in children with cystic fibrosis. Medicine & Science in Sports and Exercise 33(5):S249, 2001.
  147. Wang SS, FitzSimmons SC, O'Leary LA, Rock MJ, Gwinn ML, Khoury MJ and the U.S. Cystic Fibrosis Foundation (CFF) National Patient Registry, including Moffett KS .Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa acquisition in the first 10 years of life: A registry-based longitudinal study. .Pediatrics. 2001 Feb;107(2):274-9.
  148. Swisher AK, Yeater R, Moffett K, Baer L, Stanton B. A comparison of clinical methods to determine body composition in Cystic Fibrosis. Pediatric Pulmonology Supplement 20:328, 2000.
  149. Swisher AK, Moffett K, Baer L, Yeater R. Effect of body fat, leg muscle strength and lung function on 6-minute walk in children with cystic fibrosis. Cardiopulmonary Physical Therapy 11(4):155, Dec 2000.
  150. Zemel BS, Jawad AF, FitzSimmons S, Stallings VA and the U.S. Cystic Fibrosis Foundation (CFF) National Patient Registry, including Moffett KS. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation (CFF) National Patient Registry. J Pediatr. 2000 Sep;137(3):374-80.
  151. Konstan MW, Butler SM, Schidlow DV, et al and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.  Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol. 1999 Oct;28(4):248-54.
  152. Konstan MW, Butler SM, Schidlow DV, et al and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.. Patterns of medical practice in cystic fibrosis: part I. Evaluation and monitoring of health status of patients. Pediatr Pulmonol. 1999 Oct;28(4):242-7.
  153. Morgan WJ, Butler SM, Johnson CA, et al and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS..  Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol. 1999 Oct;28(4):231-41
  154. Shreve MR, Butler S, Kaplowitz HJ, Et al, and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.   Impact of Microbiology Practice on Cumulative Prevalence of Respiratory Tract Bacteria in Patients with Cystic Fibrosis. J Clin Microbio. 1999 37(3): 753-757.
  155. Geller DE, Kaplowitz H, Light MJ, Colin AA and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.   Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Chest. 1999 Sep;116(3):639-46.
  156. Johnson CA, Butler SM, Konstan MW, Breen TJ, Morgan WJ. and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS.  . Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. J Pediatr. 1999 Jun;134(6):734-9.
  157. Moffett, K.S., Berkowitz, F.A. Quadriplegia Complicating E. Coli Meningitis in a Newborn Infant: Case Report & Review of 22 Cases of Spinal Cord Dysfunction in a Newborn Infant.  CID 1997;25:211-14.
  158. Ayi, B., Yuhas, D., Moffett, K.S., Joyce, D., DeAngelis N. Liquid Chromatographic Determination of Thiamine in Infant Formula Products by Using Ultrasound Detection.  J Assoc. Off. Chem. 1985 (vol 68, No. 6).

 

Abstracts & Case Reports:

  1. Moffett KS. . "Incidence of  Staphylococcus saprophyticus Isolates in Children and Adults: A Retrospective Review of Microbiology Urine Cultures in a Tertiary Care Hospital 2007-2010", Irish Paedic Society Meeting, Gallway, Ireland, December 2018.
  2. Duncan CL, Chen GJ, Muther E, Lindwell J, Moffett K, Prickett M, Saavedra MT, Polineni D. A stakeholder informed feasibility study of tele-coaching to improve adherence in patients with cystic fibrosis. European Health Psychology Society, August 2018, Scotland.
  3. Gonzalez D, Blumer J, James L,Yogev R, Al-Uzri A, Bosheva M, Adler-Shohet F, Mendley S, Karimjee N, Bradley J, Espinosa C, Tsonkova E, Moffett K, Marquez L,. Simonsen KA, Stoilov S, Boakye-Agyeman F, Hornik C, Jasion T, Hernandez R, Jamieson B, Fernandes P, Cohen Wolkowiez M; on behalf of the SOLI-PEDS program. Pharmacokinetics and Safety of Solithromycin Following Intravenous and Oral Administration in Children. 2017 Pediatric Academic Societies Annual Meeting,
  4. Moffett KS, Jalali, O. "Incidence of  Staphylococcus saprophyticus Isolates in Children and Adults: A Retrospective Review of Microbiology Urine Cultures in a Tertiary Care Hospital 2007-2010", abstract #750018, April 2015 Pediatric Academic Societies Annual Meeting, San Diego, CA.
  5. Akers,SM, Kiefer AS, Moffett KS, Mitchell, ML, Barretto GA, Yoseck P. “Primary Cutaneous Aspergillosis in an Extremely Low Birth Weight Infant”, West Virginia University Poster Presentation, May 2015.
  6. Manegold EM, Szabo MM, Corman LA, Johnson RJ, Sawicki G, Black PG, Moffett KS, Duncan CL. Factor Structure of the Family Responsibility for CF Care. Society of Pediatric Psychology Annual Conference , San Diego, April 16-18, 2015.
  7. Lynch J, Patra K, Vijay, P, Mitchell M, Moffett K. Incomplete Kawasaki Disease followed by systemic juvenile rheumatoid arthritis: a conundrum. Poster #767, Society of Hospital Medicine, March 24-27, 2015, Las Vegas.
  8. Szabo MM, Bailey BA, Duncan CL, Corman LA,  Johnson RJ, Black PG, Moffett KM. Youth Anxiety and Level of Responsibility for Disease Management in Adolescents and Young Adults with Cystic Fibrosis. NACFC, Atlanta 2014.
  9. Szabo MM, Corman LA,  Duncan CL, Johnson RJ, Moffett KM, Black PG. Factors associated with treatment adherence in adolescents and young adults with cystic fibrosis. NACFC Atlanta, 2014.
  10. Szabo MM, Corman LA, Duncan CL, Johnson RJ,Urich MA, Moffett KS,Andrade O,Black PG. Family Division of Responsibility for Disease Management and Treatment Adherence in Adolescents and Young Adults with Cystic Fibrosis. Society for Philosophy and Psychology, Vancouver, 2014.
  11. Manegold EM, Szabo MM, Corman LA, Johnson RJ, Sawicki G, Black PG, Moffett KS, Duncan CL. Factor Structure of the Family Responsibility for CF Care. Society for Pediatric Psychology Annual Conference, Philadelphia 2014.
  12. Turner RB,  Biondo L, Slain D, Phillips U, Cardenas S, Moffett KS.A randomized, pilot study of continuous infusion versus intermittent infusion piperacillin-tazobactam for the treatment of pulmonary exacerbations in patients with cystic fibrosis. Pediatric Pulmonolo; 2013; S36, 333. NACFC, Salt Lake City, October 2013.
  13. Turner RB, Biondo L., Moffett KS.  Twice daily dosing of tobramycin improves attainment of pharmacokinetic parameters in pediatric patients with cystic fibrosis, Pediatric Pulmonolo; 2013; S36, 332. NACFC, Salt Lake City, October 2013.
  14. Szabo MM, Corman LA, Duncan CL, Johnson RJ, Moffett KS, Andrade O, Schurman C, Black PG. Factors Associated with Division of Responsibility for Disease Management in Youth with Cystic Fibrosis. Pediatric Pulmonolo; 2013; S36, 592. NACFC, Salt Lake City, October 2013.
  15. Corman LA, Szabo MM,  Duncan CL, Johnson RJ, Landvoigt M, Moffett KS, Andrade O, Schurman C, Black PG. Factors that predict readiness to transition from pediatrics to adult health care in cystic fibrosis. Pediatric Pulmonolo; 2013; S36, 643. NACFC, October 2013, Salt Lake City.
  16. Piechowski K, Biondo LR, Moffett KS. Evaluation of once-daily tobramycin dosing guidelines in pediatric cystic fibrosis patients in a large teaching hospital. Pediatric Pulmonolo; 2013; S36, 309. NACFC, October 2013, Salt Lake City.
  17. Szabo, M, Corman, L, Urso, L, Duncan C, Baer L, Moffett K. Association between Self-Efficacy and Division of Responsibility for Disease Management in Youth with Cystic Fibrosis. The National Conference on Pediatric Psychology, April 2013, New Orleans.
  18. Swisher  A; Mancinell, C; Landvoigt M; Moffett K; Evans M; Link J; Saffell R; Floyd H; Vincent M.  Effect of Cystic Fibrosis Related Diabetes (CFRD) on Sensation, Gait Characteristics and Balance. Orlando, North American Cystic Fibrosis Conference, October 2012.
  19. Biondo L; Rector A; Moffett K; Evaluation of patient understanding followed with education in efforts to improve adherence to vitamin supplementation at an outpatient cystic fibrosis clinic. North American Cystic Fibrosis Conference, October 2012.
  20. Cardenas S; Moffett K; Piedimonte G. Growth factor and cytokine expression in lower airways with respiratory disease Orlando, North American Cystic Fibrosis Conference, October 2012.
  21. Rieckert K et al and the iCARE study team including Moffett K. Adolescent and Parent Perceptions of their CF Care Team’s Adherence Promotion Practice and Satisfaction with Care. North American Cystic Fibrosis Conference, October 2012.
  22. Alpern A et al and the iCARE study team including Moffett K. Effects of Clinical Supervision on Treatment Fidelity in iCARE . North American Cystic Fibrosis Conference, October 2012.
  23. Alpern A et al and the iCARE study team including Moffett K. Adapting a Behavioral Adherence Intervention for Patients with Autistic Features: A Case Study. North American Cystic Fibrosis Conference, October 2012.
  24. Cardenas S, Landvoigt M, Baer L, Phillips U, Samsell L, Moffett K, Piedimonte G. . Serum Nerve Growth Factor and Brain-Derived Neurotrophic Factor as biomarkers of Cystic Fibrosis Pulmonary Exacerbation. American Thoracic Society Meeting 2011.
  25. Soares N, Moffett K. “Pediatric Experiences before third Year Clerkship in Pediatrics: A Comparison between University of Kentucky and West Virginia University Students.” Poster accepted at the Society for Developmental-Behavior Pediatrics (SDBP). San Antonio, September 2011.
  26. Phillips UK, Damirdag YY, Moffett KS. Early recognition of C2 Complement deficiency during infancy. CIS Annual Meeting, May 19-22, 2011, Chicago.
  27. Ansari H, Moffett K, McCallister M, Pergami P. Neuroretinitis with Bartonella hensalae and EBV co-infection: direct infection or Immunomodulated reaction? American Academy of Neurology (AAN), April 2010, Toronto.
  28. Nelson K, Carey M, Moffett K , Baer L, Haut M. Neurocognitive Function & White Matter Integrity in Adolescents with Cystic Fibrosis. 2009 American Academy of Clinical Neuropsychology (AACN): "Excellence in Clinical Practice" June 18-20, 2009.
  29. Stover KR, Sweet M, Moffett K.  Development, implementation and evaluation of tobramycin dosing and monitoring guidelines for adult CF patients Ped Pulmonol suppl; 31: 356, 2008.
  30. Slain D, Sarwari AR, Petros KO, McKnight R, Sager, RB, Mullett, CJ, Wilson, A, Thomas, JG, Moffett K, Palmer C, Dedhia HV. Impact of a multimodal antimicrobial stewardship program on antimicrobial us in the adult intensive care unit setting and Pseudomonas aeruginosa susceptibility. Abstract P-18 National Foundation for Infectious Diseases (NFID) Conference on Antimicrobial Resistance. June 23-25, 2008. Bethesda, MD.
  31. Sarwari AR, Petros KO, Sager RB, Wilson A, Dedhia HV, Mullett CJ, Thomas J, Miller-Canfield P, Slain D, Moffett K, Palmer C. Impact of an antimicrobial stewardship program on antimicrobial use and resistance in the intensive care units (ICU). National Foundation for Infectious Diseases (NFID) Conference on Antimicrobial Resistance. June 23-25, 2008. Bethesda, MD.
  32. Sarwari AR, Petros KO, Sager RB, Mullett CJ, Thomas J, Canfield P, ,  Dedhia HV, Wilson A, Slain D, Moffett K, Palmer C. Efforts to influence antimicrobial use and resistance at a tertiary care institution using collaborative multi-modal interventions. National Foundation for Infectious Diseases (NFID) Conference on Antimicrobial Resistance. June 23-25, 2008. Bethesda, MD.
  33. Swisher AK, Moffett K.   The effect of individualized coaching on physical activity levels and quality of life in children with cystic fibrosis. Ped Pulmonol suppl 31:385, 2008
  34. Konstan MW, Rasouliyan L Morgan WJ, Jacobs JR, Wagener JS and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS. Abstract #487 - Trends in the use of Routine Therapies in Cystic Fibrosis: 1995 – 2005, NACF October 2008.
  35. Konstan MW, Wagener JS, Pasta DJ, Silva SJ, Morgan WJ and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS. Abstract #370 – Pulmozyme (Dornase Alfa) use is associated with a slower rate of lung function decline in patients with Cystic Fibrosis, NACF October 2008.
  36. Wagener JS, Rasouliyan L, Pasta DJ, Mabie J, Morgan WJ,  Konstan MW and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, including Moffett KS. Abstract #440 - Practice Patterns for Treating Respiratory Exacerbations in Cystic Fibrosis, NACF October 2008.
  37. Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, Wagener  JS for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis, , including Moffett KS . Abstract #445 - Year-to-Year Changes in Lung Function in Individuals with Cystic Fibrosis, NACF October 2008.
  38. Sawicki GS, Rasouliyan L, Pasta DJ, McMullen AH, Wagener JS, McColley SC, Quittner AL for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis,  including Moffett KS . Abstract #554 - Longitudinal Assessment of Changes in Health Status and Health-Related Quality of Life in Cystic Fibrosis, NACF October 2008.
  39. Sarwari AR, Petros KO, Sager RB, Wilson A, Dedhia HV, Mullett CJ, Thomas J, Miller-Canfield P, Slain D, Moffett KS, Palmer HC. Impact of an antimicrobial stewardship program on antimicrobial use and resistance in intensive care units (ICU). P18 Poster Presentation, 2008 Annual Conference on Antimicrobial Resistance, Baltimore, Maryland.
  40. Sarwari AR, Petros KO, Sager RB,  Mullett CJ, Thomas J, Miller-Canfield P, Dedhia HV, Wilson A, Slain D, Moffett KS, Palmer HC. Efforts to influence antimicrobial use and resistance at a tertiary care institution using collaborative multifaceted interventions. S10 Oral Presentation, 2008 Annual Conference on Antimicrobial Resistance, Baltimore, Maryland.
  41. Konstan MW, Liou T, Strausbarugh S, Ahrens R, Kanga J, Graff G, Moffett K, Millard S, Nasr S, Vezna M, Spenard J, Granden J. Efficacy & Safety of a Revised Formulation of Enteric Coated Micropheres (ULTRASE® MT20) of Pancreatic enzymes in the Treatment of Pancreatic Insufficiency in Cystic Fibrosis.  Digestive Disease Week, San Diego, May 2008.
  42. Swisher AK, Moffett KS. The effect of individualized coaching on physical activity levels and quality of life in children with cystic fibrosis. State of West Virginia AAP Meeting, Charleston WV, April 4, 2008.
  43. Swisher AK, Erickson M, Dayoub J, Chapman J, Melody E, Scott E, Vance A, Moffett K.  Perceived facilitators and barriers of physical activity in adolescents with cystic fibrosis and their healthy peers. Ped Pulmonol suppl 30:359, 2007.
  44. Swisher AK; Baer L; Bonner D; Moffett K.  Effect of Voluntary Activity, Lung Function and Nutritional Measurements on 3-Minute Step Test Performance in Children with Cystic Fibrosis Abstract accepted for AACVPR annual meeting September 2006, Charleston, WV.
  45. Swisher, A; Moffett, K; Baer, L; Bonner, D; Haddox, S; Layfield, M; Morris, A; Pile, J.  The relationship of lung function, nutritional status and voluntary activity to fitness level in children/adolescents with CF compared to healthy peers.  Ped Pulmonol suppl 28:319, 2005, North American CF Conference, Baltimore, October 2005.
  46. Swisher AK,  Moffett KS,  Baer LS,  Singleton  W.  The Effect of Cystic Fibrosis on Recovery from Orthopedic Trauma: A Case Study. Poster presented at 2005 Presentation at 2005 Combined Sections Meeting of the American Physical Therapy Association: Feb 27, 2005
  47. Swisher A; Moffett K; Baer L; Wilson D; Singleton W.  The effect of cystic fibrosis on recovery from orthopedic trauma: A case study.  Cardiopulmonary Physical Therapy 14(4):26, 2004.
  48. Bernard RS, Cohen LL, Moffett KS. Use of a Token Economy to Increase Exercise in Children with Cystic Fibrosis, Abstract accepted for AABT meeting: Boston, November 2003.
  49. Bernard R S, Cohen LL, Moffett K, Swisher A, Baer L; Increasing Exercise in Children with Cystic Fibrosis: How Token Economics can help. Abstract accepted for North American CF Conference, Anaheim, October 2003.
  50. McClellan C B, Cohen LL, Moffett KS.  Evaluation of Time-Out to Manage Children’s Noncompliance with Cystic Fibrosis Treatment. Abstract accepted for North American CF Conference, Anaheim, October 2003.
  51. Swisher AK, Moffett K, Baer L, Stanton B. Sex Differences in Predictors of 6-minute Walk Performance in Children with Cystic Fibrosis.  AACVPR, September 2002.
  52. Swisher AK, Moffett K, Baer L, Yeater R.  Effect of body fat, leg muscle strength and lung function on 6-minute walk in children with cystic fibrosis. APTA, San Antonio, February 2001.
  53. Swisher AK, Yeater R, Moffett KS, Baer L, Stanton B.  A comparison of clinical methods to determine body composition in Cystic Fibrosis.  Pediatric Pulmonology Supplement.  20:328, 2000.
  54. Swisher AK, Yeater R, Moffett K, Baer L, Stanton B. A comparison of clinical methods to determine body composition in Cystic Fibrosis. Pediatric Pulmonology Supplement 20:328, 2000.
  55. Swisher AK, Moffett K, Baer L, Yeater R. Effect of body fat, leg muscle strength and lung function on 6-minute walk in children with cystic fibrosis. Cardiopulmonary Physical Therapy 11(4):155, Dec 2000.
  56. Moffett KS, Nesheim SR, Lee FK, Stewart JA, Sawyer MK, Nahmias AJ.  Lymphoid Interstitial Pneumonitis (LIP): Serum Factors in LIP+ and LIP- Children with HIV associated with Pathogenesis. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 5, 1994.
  57. Moffett KS, Berkowitz FA.  Quadriplegia Complicating E. coli Meningitis in a Newborn Infant: Case Report & Review of 22 cases of Spinal Cord Dysfunction in Children.  Southern Society for Pediatric Research. New Orleans, February, 1995.

     Books & Book Chapters:

  1. Moffett KS.  Cystic Fibrosis. 2018; 8th edition Textbook of Pediatric Infectious Diseases, Feigin, Cherry, Demmler-Harrison, Kaplan, editors.
  2. Moffett KS.  Cystic Fibrosis. 2014; 7th edition Textbook of Pediatric Infectious Diseases, Feigin, Cherry, Demmler-Harrison, Kaplan, editors.
  3. Moffett KS. Pseudomonas and Cystic Fibrosis in Manual of Infectious Diseases, Burdette & Yu, editors, ESun Technologies, publisher. 2011.
  4. Moffett KS. Pseudomonas and Cystic Fibrosis. 2008; 2nd edition 2011. www.antimicrobial.com,
  5. Fujitanii S, Moffett KS, Paterson D. Pseudomonas aeruginosa. 2008; 2nd edition 2011. www.antimicrobial.com.
  6. Moffett, KS, Aronoff, SC, Osteomyelitis in Pediatric Infectious Diseases, 2nd Edition, ed. Jansson & Baltimore, WB Saunders, 2001.
  7. Moffett, KS, Aronoff, SC  Infectious Arthritis in Pediatric Infectious Diseases, 2nd Edition, ed. Jansson & Baltimore, WB Saunders, 2001.
  8. Moffett, KS, Aronoff, SC, Diskitis in Pediatric Infectious Diseases, 2nd Edition, ed. Jansson & Baltimore, WB Saunders, 2001.

Awards

Western PA Chapter, CF Foundation, Top Volunteer Award to Mountain State CF Center, February 2, 2017.

Monongalia County Health Department Hero of Public Health Award, Recognition of Public Assistance, August 22, 2016.

BRAVO Award, member of Ebola Preparedness Team, WVU Healthcare, 2014-2015.

West Virginia Children’s Hospital Award of Excellence, February 7, 2015, presented at Children’s Hospital Gala, Waterfront Hotel.

Nomination, Innovator of the Year, West Virginia University, September 2014.

2014 Advocate for Children Award, State of West Virginia Chapter, American Academy of Pediatrics.

Nominated, Chancellor’s Award, West Virginia University, May 2014.

Nominated, Dean’s Award, West Virginia School of Medicine, 2013.

Adolescent Immunization Award, West Virginia Immunization Network 8th Annual Award - Capitol Complex in Charleston 2013.

Alpha Omega Alpha, 2012.

Nominated, Dean’s Award, West Virginia School of Medicine, 2012.

North American Cystic Fibrosis Conference (NACFC),  iCARE study, Most Diversity in CF Care Team; Baltimore; October 2010.

Merck’s 2010 Vaccination Service Award.

Nomination for Women in Science & Health Excellence Award for 2010; WVU Health Science Center.

TEAM (Together Everyone Achieves More!) Award, 2010, WVUH Recognition for 2009-2010 Flu/ H1N1 work.

Recognition from the American Board of Pediatrics for Quality Improvement  (QI) work accomplished in the WVU CF Center, 2009.

Nomination for Women in Science & Health Excellence Award for 2009, WVU Health Science Center.

Dean’s Nomination to attend Mid-career Development Seminar, Scottsdale, December 2006, Association of American Medical Colleges (AAMC).

2005 Nomination, Teacher of the Year, Class of 2005 West Virginia University School of Medicine.

2000 Outstanding Teaching Division of the Year (Infectious Diseases), Department of Pediatrics, West Virginia University.

1999 Outstanding Teacher of the Year, Department of Pediatrics, West Virginia University.

1998 Outstanding Teacher of the Year, Department of Family Medicine, Pinnacle Health Systems, Harrisburg, PA.

1992 Golden Apple Teaching Award, Children’s Hospital Medical Center of Akron, OH.

1991 Resident of the Year, Children’s Hospital Medical Center of Akron, OH.

 

Additional Info

Bright Spots and Challenges in Children's Health

Research Program

Director, Mountain State Cystic Fibrosis Center

Research Interests

Dr. Moffett is passionate about excellence in the clinical care and research of patients with infectious diseases (ID) and cystic fibrosis (CF). During over two decades at WVU she has built a CF center from a small unaccredited clinic to a highly successful separately accredited adult and pediatric centers, which focus on patient care, teamwork, quality improvement, and research. The pediatric infectious diseases division has grown to 3 fulltime physicians, 2 nurses and a pharmacist with a focus on excellent patient care, antimicrobial stewardship, scholarly work and clinical research. The CF care team consists of 4 physicians, 2 nurses, 2 nurse practitioners, 2 social workers, 1 dietician, 1 research coordinator, 1 respiratory therapist, 1 pharmacist, 1 physical therapist and collaboration with a research psychologist.

Working in collaboration as teams, peds ID and CF care, both strive for compassion and respect for all patients and families, excellence in everything one does, with consensus and teamwork on a daily basis, and well-being in our teams’ personal and professional lives. Research is a priority, offering pediatric infectious disease and cystic fibrosis clinical trials, investigator-initiated research, and basic science collaboration at WVU.

Patient Care Information

Medical Specialties

  • Pediatric Infectious Diseases
  • Pediatrics

Board Certifications

  • Pediatric Infectious Diseases, American Board of Pediatrics
  • Pediatrics, American Board of Pediatrics

Special Training

  • Fellowship, Pediatric Infectious Disease
    Emory University, Atlanta, GA, 1994
  • Residency, Pediatrics
    Children's Hospital Medical Center of Akron, OH, 1992